The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
Open accessAbstract
Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clinical trials (phases I to III) to treat Parkinson’s disease, and they will probably soon reach the market. The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia. At present it is believed that A2AR antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson’s patients. However, a considerable body of data indicates that in addition to ameliorating motor symptoms, adenosine A2AR antagonists may also prevent neurodegeneration. Despite these promising indications, one further issue must be considered in order to develop fully optimized anti-parkinsonian drug therapy, namely the existence of receptor (hetero)dimers/oligomers of G protein-coupled receptors, a topic currently the focus of intense debate within the scientific community. Dopamine D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine receptors. Thus, the development of heteromer-specific A2A receptor antagonists represents a promising strategy for the identification of more selective and safer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827 · cited 2×
“…when LPS-injected Cx3Crl-eGFP transgenic mice that specifically express the eGFP protein in microglia (Davalos et al., 2005; Haynes et al., 2006; Nimmerjahn et al., 2005) are treated with the A2AR antagonist SCH-58261(10), the repulsion of activated microglial processes from ATP at the inflamed…”
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 1×
“Following chronic activation, microglia typically assume an amoeboid morphology with highly retracted processes (Block et al., 2007; Hanisch & Kettenmann, 2007; Kreutzberg, 1996; Stence et al., 2001).”
ATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913
Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
Microglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676 · cited 2×
“It is now well established that microglia continuously engage in minor transient and self-limiting repairs that rapidly resolve such situations and generally go unnoticed (Hanisch & Kettenmann, 2007).”
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 2×
“By contrast, the non-specific adenosine antagonist caffeine loses its motor stimulant effect after repeated administration (Fredholm et al., 1999; Halldner et al., 2000).”
Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90229-w · Cited by 2,045 · cited 1×
“Microglia represent a source of neurotoxic factors that can further drive neuronal damage, and the extreme vulnerability of the SNc to oxidative stress is likely correlated with a greater microglial density as compared with in other brain regions (Lawson et al., 1990).”
Cited by
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
G Protein–Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives
Ferré, S., Casadó, V., Devi, L. A., Filizola, M., Jockers, R., Lohse, M. J., Milligan, G., Pin, J.-P., & Guitart, X. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008052 · Cited by 570
Self-citationHow does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., & Tamburin, S. (2016) · Parkinson's Disease · doi:10.1155/2016/9832839 · Cited by 369
Adenosine A 2A Receptor as a Drug Discovery Target
de Lera Ruiz, M., Lim, Y.-H., & Zheng, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4011669 · Cited by 276
Medicinal chemistry of adenosine, P2Y and P2X receptors
Jacobson, K. A., & Müller, C. E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.001 · Cited by 262
Self-citationFerré, S., Bonaventura, J., Zhu, W., Hatcher-Solis, C., Taura, J., Quiroz, C., Cai, N.-S., Moreno, E., Casadó-Anguera, V., Kravitz, A. V., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00243 · Cited by 100
Self-citationCortico-striatal circuits: novel therapeutic targets for substance use disorders
Kravitz, A. V., Tomasi, D., LeBlanc, K. H., Baler, R., Volkow, N. D., Bonci, A., & Ferré, S. (2015) · Brain Research · doi:10.1016/j.brainres.2015.03.048 · Cited by 63
Self-citationFerré, S., Díaz-Ríos, M., Salamone, J. D., & Prediger, R. D. (2018) · Journal of Caffeine and Adenosine Research · doi:10.1089/caff.2018.0017 · Cited by 52
“the dorsal striatum has fostered the rational of applying A2AR antagonists in Parkinson’s disease.(12,13) However, the A2AR–D2R heteromer is also localized in the ventral striatum, involved in more motivational aspects of behavior.”
BackgroundMethodSelf-citationLowe, P. T., Dall'Angelo, S., Mulder‐Krieger, T., IJzerman, A. P., Zanda, M., & O'Hagan, D. (2017) · ChemBioChem · doi:10.1002/cbic.201700382 · Cited by 19
Metadata
- Authors
- Armentero, M. T., Pinna, A., Ferré, S., Lanciego, J. L., Müller, C. E., & Franco, R.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 132
- Issue
- 3
- Pages
- 280-299
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2056849709
- Cited by
- 192
- References
- 30
- FWCI
- 9.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.